Fig. 5From: Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery deviceMean release of nerve growth factor from nerve-growth-factor-encapsulated cell biodelivery implants represented in nanograms per patient per 24 h, before implant (pre-implant) and at day 2 after explant (post-explant day 2) in the four patientsBack to article page